Phase 2 rGBM
SonALAsense is now recruiting for a 50 subject, 3-part Phase 2 trial in recurrent glioblastoma.
Phase 2 rGBM Clinical Trial Design
Part 1 will be an initial drug dose + focused ultrasound energy escalation phase, where patients will be treated with two dose levels of SONALA-001 in combination with one of three dose levels of focused ultrasound as a single dose of SDT.
Part 2 is a schedule escalation phase where 6 patients will be treated twice with SDT. Then 6 patients will be treated three times at the recommended dose from part 1.
Part 3 will be an expansion cohort, where patients will be treated at the recommended SDT dose from part 1 and the recommended SDT schedule from part 2.
For more details visit our ClinicalTrials.gov listing: https://www.clinicaltrials.gov/ct2/show/NCT05370508